Rudy Mrad, MD

UT Southwestern Medical Center

Research fellow at UTSW

Poster(s):

• 1417 - Acalabrutinib Monotherapy versus Acalabrutinib plus Obinutuzumab Combination Therapy in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A ‘Real-World’ Study of Efficacy and Safety

• 1715 - Real-World Outcomes Following Pemivibart (Pemgarda™) for COVID-19 Prophylaxis in Immunocompromised Patients with Hematologic Malignancies